The Science Behind GutID: Precision, Innovation, and Impact
Unlock the full potential of your health with GutID's cutting-edge technology. Our tests deliver the complete picture of your gut bacteria with precise, high resolution, strain-level insights and personalized recommendations, setting a new standard in microbiome testing. Experience science-backed results designed to transform your health and wellness.
Our Technology vs. Others
Our Titan-1 technology generates a unique “fingerprint” for each strain- even for unknown strains providing accurate and complete data for actionability and broad clinical application. For example, Without knowing the strain, there is no way to know a given strain of E.coli is toxic or harmless.
Technology Featured In
Intus Bio: Innovating the Future of Microbiome Science
Intus Biosciences was founded to solve three key challenges in microbiome science: universality, specificity, and taxonomy independence. Their patented bacterial lysis ensures accurate representation of every strain in a sample, enabling precise comparisons of bacterial abundance. With advanced amplicon technology and machine learning, they deliver high-throughput, strain-level analysis that identifies both pathogenic and health-promoting bacterial signatures.
Unlike traditional methods relying on incomplete databases, Intus Bio’s innovative approach identifies and tracks novel strains, addressing the immense diversity of bacteria linked to human health. As the powerhouse behind GutID, Intus Bio is transforming microbiome research and empowering better healthcare outcomes.
About Us
At GutID, we are inspired by the groundbreaking work of two pioneers in microbiome science.
Dr. Mark Driscoll is the co-founder of Intus Biosciences, and inventor of the revolutionary GutID microbiome test. Mark earned his Ph.D. at the University of Rochester and was a post-doctoral fellow at NCI-Frederick Cancer Research and Development Center. With over 3 decades of experience across microbiology, immunology, biochemistry and biophysics, Mark is at the forefront of advancing gut health research. At 454 Life Sciences/Roche he led the development of the GS-20, the world’s first next-generation (NGS) sequencer, which revolutionized genetic research, diagnostics and the understanding of the microbiome. His dedication to understanding the role of gut bacteria in wellness, has earned him recognition as a published researcher and international speaker.
Dr. Dan Fasulo, our bioinformatics innovator, has spent his career creating computational tools that power microbiome discovery. Dan earned his Ph.D. at the University of Washington and led bioinformatics and software development at 454 Life Sciences. A key contributor to the GS-20 development, Dan also played a vital role in landmark genomic projects at Celera and later founded Pattern Genomics, which became part of Intus Biosciences. His work bridges science and technology to drive breakthroughs in precision health.
Together, their shared passion for innovation and improving lives through science led to the creation of GutID—a company dedicated to empowering individuals with actionable insights into their gut health.